GSK Selects Genedata Biologics as Antibody Discovery Platform - - BioPharm International

ADVERTISEMENT

GSK Selects Genedata Biologics as Antibody Discovery Platform



Genedata, a provider of software solutions for drug discovery and life science research, reported that Biopharm R&D at GlaxoSmithKline (GSK) has selected Genedata Biologics as a R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.

The system can record, manage, and process data from GSK's antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies. Genedata reports that the system can help to improve data quality, improve efficiency through upload and export of instrument data, and increase experimental throughput. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats.

Source: Genedata

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here